US20030031710A1 - Process and composition for temporarily suppressing pain - Google Patents
Process and composition for temporarily suppressing pain Download PDFInfo
- Publication number
- US20030031710A1 US20030031710A1 US10/200,280 US20028002A US2003031710A1 US 20030031710 A1 US20030031710 A1 US 20030031710A1 US 20028002 A US20028002 A US 20028002A US 2003031710 A1 US2003031710 A1 US 2003031710A1
- Authority
- US
- United States
- Prior art keywords
- composition
- acid
- tissue
- irritant
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 58
- 230000008569 process Effects 0.000 title claims abstract description 54
- 208000002193 Pain Diseases 0.000 title claims abstract description 24
- 239000002085 irritant Substances 0.000 claims abstract description 70
- 230000007794 irritation Effects 0.000 claims abstract description 61
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims abstract description 50
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000002253 acid Substances 0.000 claims abstract description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- 239000007787 solid Substances 0.000 claims abstract description 22
- 235000021096 natural sweeteners Nutrition 0.000 claims abstract description 18
- 235000013615 non-nutritive sweetener Nutrition 0.000 claims abstract description 18
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 16
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 15
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 29
- 235000003599 food sweetener Nutrition 0.000 claims description 27
- 239000003765 sweetening agent Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 230000000975 bioactive effect Effects 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 16
- 239000008122 artificial sweetener Substances 0.000 claims description 15
- 235000015165 citric acid Nutrition 0.000 claims description 13
- 235000015218 chewing gum Nutrition 0.000 claims description 12
- 229940112822 chewing gum Drugs 0.000 claims description 11
- 210000000929 nociceptor Anatomy 0.000 claims description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 108010011485 Aspartame Proteins 0.000 claims description 7
- 239000000605 aspartame Substances 0.000 claims description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 7
- 235000010357 aspartame Nutrition 0.000 claims description 7
- 229960003438 aspartame Drugs 0.000 claims description 7
- 239000012867 bioactive agent Substances 0.000 claims description 7
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000008247 solid mixture Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- -1 antifungals Substances 0.000 claims description 4
- 235000011087 fumaric acid Nutrition 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims 5
- 229940081974 saccharin Drugs 0.000 claims 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 5
- 150000007524 organic acids Chemical class 0.000 claims 4
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 36
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 20
- 210000004877 mucosa Anatomy 0.000 abstract description 19
- 235000005979 Citrus limon Nutrition 0.000 abstract description 15
- 230000002378 acidificating effect Effects 0.000 abstract description 9
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 9
- 244000248349 Citrus limon Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- 239000000243 solution Substances 0.000 description 16
- 244000131522 Citrus pyriformis Species 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 210000001508 eye Anatomy 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 239000003929 acidic solution Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000207199 Citrus Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000000551 dentifrice Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 239000002973 irritant agent Substances 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940006465 strontium cation Drugs 0.000 description 2
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000089742 Citrus aurantifolia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000333459 Citrus x tangelo Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000016649 Copaifera officinalis Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002871 Dammar gum Polymers 0.000 description 1
- 239000004860 Dammar gum Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 239000004321 EU approved sweetener Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000004868 Kauri gum Substances 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000003293 Magnolia grandiflora Species 0.000 description 1
- 235000008512 Magnolia grandiflora Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Definitions
- the present invention is directed to a process and composition for treating the surface of the skin or other tissue with an active compound substantially without irritation. More particularly, the invention is directed to a process and composition for suppressing pain topically on the eye, skin or mucosa tissue.
- compositions that are applied to the skin include cosmetics, sunscreens and the like.
- Other compositions often include a pharmaceutical agent such as an antibiotic or bactericide for treating the surface of the tissue.
- Topically applied compositions are generally in the form of liquids, creams, lotions and gels.
- the compositions that are applied topically contain various components, which inherently cause irritation and inflammation when applied to the skin or the mucosa.
- the occurrence and frequency of the irritation can vary depending on the person, the specific components in the composition and the various components present.
- Common symptoms of irritation from topically applied compositions include itching, stinging, burning, tingling, tightness, redness and swelling.
- the irritation can be due to the direct effect on the skin or the mucosa of the active ingredient or the carrier or in response to the immune system directly toward the chemicals alone or in combination with the skin components.
- ingredients used in topically applied products are known irritants or are potentially irritating, especially for certain people with some allergies or sensitivities.
- Ingredients which can act as irritants include solvents, fragrances, preservatives, propellants, and pharmaceutical agents.
- Examples of common topical compositions, which can cause irritation include exfolients and skin renewal agents, antiperspirants, antihistamines, anti-inflammatory agents, skin protective agents, insect repellants and sunscreens. Where more than one irritant compound is present, the effects can be additive.
- various components can interact with each other to cause irritation which might not occur when used alone.
- U.S. Pat. No. 5,716,625 to Hahn discloses the use of a strontium metal cation to reduce irritation. It is proposed that the cation interacts with the epidermis nerve cells to prevent or counteract the sensation of irritation by interfering with the irritation inducing components of the skin cells.
- the strontium cation is proposed to alter the ability of the epidermal cells to depolarize by blocking or interfering with ion channel or pump operation or by altering the transmembranal action potential. It has also been proposed that the strontium cation acts to inhibit or modify the action of skin cell protease or other irritation inducing components.
- the human skin and mucosa tissue presents a complicated structural and sensory environment.
- the skin contains nerves and highly specific sensory cells that are specialized. These cells are developed to differentiate the stimuli leading to specific sensation such as pain.
- nerves in the skin are responsive to native or foreign chemicals such as proteases, prostaglandins, complement system molecules, allergens and the like. Agents that are effective in combating one stimulus are often ineffective against another stimulus.
- the present invention is directed to a process and composition for inhibiting pain and irritation that is normally caused by topically applying a bioactive agent or medicament. More particularly, the invention is directed to a process for treating tissue with a liquid or solid composition and temporarily suppressing pain of the tissue being treated.
- a primary object of the invention is to provide a process for treating skin or mucosa tissue with a composition where the composition contains an active ingredient and an effective amount of an anti-irritant.
- Another object of the invention is to provide a process for treating tissue by contacting said tissue with a composition comprising a water soluble carrier, an effective amount of a bioactive agent, and anti-irritant to temporarily suppress pain and irritation of the tissue.
- a still further object of the invention is to provide a process for topically treating mucosa with a water soluble solid composition containing a pharmaceutical agent and an effective amount of an anti-irritant.
- Another object of the invention is to provide a process for temporarily suppressing pain and irritation by topically applying a solid composition containing an effective amount of an anti-irritant.
- a further object of the invention is to provide a process and composition for removing calculus from tooth surfaces substantially without irritation to the gums and the tooth by applying a solid composition containing an acidic or alkaline material and an effective amount of an anti-irritant.
- Another object of the invention is to provide a solid composition containing an active component for applying topically to the skin or mucosa, where the composition contains a pain suppressing amount of saccharine.
- a further object of the invention is to provide a process for topically treating skin or mucosa with a water soluble solid composition capable of forming a solution having a pH of about 4.0 or less and a pain and irritation suppressing amount of a synthetic sweetener.
- the objects and advantages of the invention are basically attained by providing a process for treating tissue of an animal with at least one bioactive compound by providing a water soluble composition comprising, at least one bioactive compound and at least one sweetener.
- the sweetener is included in an effective amount to block pain receptors temporarily in animal tissue upon release from the composition.
- the composition is applied to the tissue of the animal in an effective amount to treat the tissue with the bioactive compound and to suppress pain and irritation of the tissue.
- the objects of the invention are further attained by providing a process for removing calculus and other deposits from the surface of the teeth of an animal comprising the steps of: providing a water soluble composition containing an edible acid in an amount to form a solution having a pH of about 6.0 or less and at least one sweetener in an amount to suppress irritation of gum tissue.
- the water soluble composition is placed in the mouth or applied to the surfaces of the teeth for an effective amount of time to substantially remove calculus and deposits from the teeth.
- the objects and advantages of the invention are also attained by providing a process for temporarily suppressing pain receptors and reducing irritation of the tissue of an animal comprising the steps of: providing a solid or semi-solid carrier, at least one water soluble or water dispersible bioactive compound and at least one sweetener.
- the sweetener is present in an effective amount to suppress the pain receptors of the tissue and to reduce pain and irritation to the tissue caused by the composition.
- the tissue is contacted with the bioactive compound in an amount to treat the tissue with the bioactive compound substantially without irritation to the tissue.
- compositions comprising a solid or semi-solid carrier, at least one bioactive component and a pain and irritation suppressing amount of a non-nutritive sweetener.
- the present invention is directed to a process and composition for temporarily suppressing pain and irritation by applying an effective amount of an anti-irritant to the skin, mucosa, eye or other tissue. More particularly, the invention is directed to a process and composition for topically delivering a composition to a specific site on a patient where the composition contains an anti-irritant in an amount to inhibit irritation to the delivery site.
- the composition of the invention in preferred embodiments contains at least one active component such as a biologically active agent, a suitable vehicle or carrier, and an anti-irritant.
- the carrier can be a liquid, solid or semi-solid.
- the composition is an aqueous solution.
- the composition can be a dispersion, emulsion, gel, lotion or cream containing a vehicle for the various components.
- the primary vehicle is water.
- the liquid vehicle can include other materials, such as alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired consistency and viscosity.
- the composition that is applied to the treatment site can be a liquid or solid depending on the treatment site.
- the composition can include a solid or semi-solid carrier when the composition is used as a lozenge or tablet for the oral delivery of an active component.
- the composition can be used as an implant or a suppository.
- Liquid carriers are desirable in some instances for oral use, such as mouth washes, gargle solutions and the like. Liquid carriers are also desirable for irrigation solutions for irrigating a cut, wound or surgical site, such as during surgical removal of a tumor and irrigating the bladder or vagina.
- the invention is primarily directed to a composition containing an anti-irritant agent in an effective amount that is capable of suppressing the pain receptors in the tissue to inhibit pain and irritation to the area being treated topically with the composition.
- the invention is further directed to a process of treating tissue or applying an active agent to an area with little or no irritation. It has been found that various natural and particularly artificial or synthetic non-nutritive sweeteners are able to provide a temporary suppression of pain and irritation to the area being treated when applied topically. In particular, it has been found that compositions using an artificial, non-nutritive sweetener in amounts in excess of the amounts conventionally used for sweetening a food product have an anti-irritant effect.
- the natural sweeteners and particularly the synthetic, non-nutritive sweeteners are able to block the pain receptors at the site on the tissue being treated.
- Patients using the compositions of the invention when applied topically to skin, mucosa, and other tissue, experience a reduction in pain and irritation than would otherwise occur and without numbness or loss of feeling to the treated area.
- the anti-irritant is an artificial non-nutritive sweetener included in the composition in an effective amount to suppress or inhibit pain and inhibit irritation caused by topically applying the composition to the skin, mucosa or other tissue.
- the artificial, non-nutritive sweetener can be a commercially available sweetener such as saccharine and the salts thereof, aspartame, cyclamates and the salts thereof, acetesulfone K, and mixtures thereof.
- the non-nutritive sweetener is sodium saccharine obtained commercially as a food sweetener, such as the product available under the trademark Sweet-N-Low.
- the commercially available food sweeteners typically include a bulking and dispersing component such as dextrose. The bulking and dispersing components of the commercial sweeteners do not interfere with the anti-irritant effect of the sweetener.
- Sodium saccharine is generally preferred since it is readily soluble in water and readily available.
- the anti-irritant is a natural sweetener such as a monosaccharide, disaccharide or polysaccharide.
- Suitable natural monosaccharide sweeteners include glucose and fructose.
- Other sweeteners include, arabinose, xylose, ribose, mannose, galactose, dextrose, sorbose, sorbitol, mannitol, and mixtures thereof.
- Suitable disaccharides include, sucrose, lactose, maltose and cellobiose.
- the polysaccharides can include partially hydrolyzed starch, dextrin, stevioside or corn syrup salts.
- the natural sweeteners can be used in combination with one or more non-nutritive sweeteners.
- Other suitable sweeteners include sorbitol, mannitol, xylitol and the like.
- the composition of the invention includes a carrier capable of delivering the anti-irritant and the active ingredient.
- the preferred liquid carrier is water, although other pharmaceutically acceptable carriers can be used depending on the intended use of the composition.
- the carrier can include various co-solvents, dispersing agents or emulsifiers as known in the art.
- the carrier is water substantially in the absence of emulsifiers or dispersing agents.
- the carrier can also contain various thickening or gelling agents to obtain the desired consistency or viscosity.
- the vehicle for topical application to the skin can include various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
- glycols such as glycerin
- lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
- the vehicles used for compositions for treating mucosa are limited primarily by the toxicity of the vehicle to the tissue.
- the anti-irritant is preferably dissolved or dispersed in the liquid carrier in an amount to provide the desired anti-irritant effect.
- the amount of the anti-irritant will depend on the particular anti-irritant being used, and the active ingredient responsible for the irritation since some active ingredients are more likely to cause irritation.
- the sensitivity of the intended tissue being treated also determines the amount of the anti-irritant in the composition.
- the anti-irritant is an artificial sweetener.
- a particularly suitable sweetener is the commercially available sodium saccharine.
- the sodium saccharine is included in the amount of about 10% to about 40% by weight based on the total weight of the carrier.
- the amount of the non-nutritive can vary depending on the other components of the composition.
- the non-nutritive sweetener is used in similar amounts for liquid and solid carriers.
- the sodium saccharine is included in the amount of 15% to about 30% by weight based on the total weight of the carrier.
- Commercially available saccharine products sold as ready-to-use sugar substitutes contain about 60% by weight saccharine, with the remaining amount being made up of dextrose and other bulking, dispersing and anti-caking agents.
- sodium saccharine products are used in amounts, typically about 25% to 35% by weight, to provide the desired saccharine concentrations in the final product.
- Other artificial non-nutritive sweeteners such as aspartame and cyclamates and salts thereof are used in similar amounts as the saccharine.
- the artificial non-nutritive sweetener is included in an amount to form a saturated solution.
- the natural sweeteners such as sucrose
- the carrier is a liquid the natural sweetener forms a saturated or near saturated solution.
- the anti-irritant is an artificial non-nutritive sweetener to avoid the stickiness associated with topical applications of natural sweeteners.
- the composition is an aqueous medium containing a mixture of a natural sweetener, such as sucrose or sorbitol, and an anti-irritant amount of a synthetic sweetener such as sodium saccharine.
- the composition also contains an active compound which can be at least one bioactive ingredient in an amount to provide effective treatment of the patient in need thereof.
- the bioactive ingredient can be, for example, an antifungal, anti-inflammatory, antibiotic, analgesic, immunosuppressive agent, and mixtures thereof.
- the anti-inflammatory agents can be steroidal, non-steroidal or salicylates. Examples of anti-inflammatory agents include acetylsalicylic acid (aspirin), ibuprofen and acetaminophen.
- the suitable antibiotics can include aminoglycosides, cephalosporins, macrolides, monobactrams, penicillins, quinolines, sulfonamides and tetracyclines as known in the art.
- immunosuppressive agents include cyclosporin, azathioprine and Rh o (D)immune globulin.
- active ingredients are intended to be exemplary of suitable pharmaceutically active components. It will be understood that other bioactive ingredients can be used that are capable of inducing a desired response or treating a particular condition.
- the amounts of the active compounds in the composition are standard concentrations for topically applied components as known in the art.
- the composition includes a pharmaceutically acceptable or edible acid to adjust the pH below 7.0, and generally below about pH 6.0.
- Suitable acids include, for example, citric acid, acetic acid, ascorbic acid, malic acid, adipic acid, fumaric acid, and mixtures thereof.
- the acid functions as a bioactive compound for certain topical applications.
- the acid is in the form of a citrus juice from lemons, limes, oranges, grapefruits, tangerines, tangelos, and mixtures thereof
- the citrus juice is fresh squeezed juice or juice obtained from reconstituted concentrate.
- the most preferred citrus juice is fresh lemon juice.
- the composition can contain a mixture of citric acid and ascorbic acid.
- the acid which can be a citrus juice
- the acid is included in an amount to provide a solution having a pH of about 2.0-6.0, depending on the desired pH for the tissue being treated.
- the composition has a pH of about 2.0-3.0 for some topical applications to the skin and mucosa.
- Fresh lemon juice for example, typically has a pH of about 2.3 to 2.4.
- the acid compound is included in an amount to produce a solution having a pH of about 2.0-6.0, and preferably a pH of about 2.0-5.0.
- Acidic agents are known generally to produce a burning and irritating effect when applied to sensitive tissue such as scratches or cuts on the skin, mucosa and the eye. It has been found that the anti-irritants of the invention, and particularly sodium saccharine, has an anti-irritant effect on tissue to inhibit the irritation caused by the acid added in an effective amount. Moreover, pH measurements of acid solutions containing varying amounts of sucrose and/or sodium saccharine have shown that the sucrose and sodium saccharine do not significantly alter the pH of the acidic solution. One aspect of the invention is based on the use of an anti-irritant agent without significantly adjusting the pH of the acidic solution.
- the pH of the composition is adjusted as necessary to dissolve a desired active compound.
- a desired active compound For example, certain compounds are stable or soluble only in acid or alkaline solutions and cannot be easily dissolved without adjusting the pH.
- the anti-irritant of the invention enables the use of acidic or alkaline solutions containing compounds that are insoluble or unstable at neutral pH without irritation normally associated with acidic or alkaline solutions.
- acid solutions having a pH of less than about 5.0 can be applied to the skin or mucosa tissue substantially without irritation.
- composition in one form of the invention is an aqueous solution containing an active ingredient for applying topically to the skin, mucosa, or other tissue.
- Compositions for applying topically to the tissue preferably contain an antibiotic, antibacterial agent, analgesic or anti-inflammatory, and an anti-irritating amount of a natural or artificial sweetener.
- the composition is particularly suitable for treating minor cuts, scratches, and abrasions on the skin substantially without irritation. It has been found that an aqueous solution containing 25% to 35% by weight sodium saccharine and an acid, such as ascorbic, citric or acetic acid to produce a solution having a pH of about 2.5-3.0, can be applied to scratches and minor cuts on the skin substantially without irritation.
- the sodium saccharine is believed to provide a temporary suppression of the nerve endings on the skin to prevent or reduce the irritation. It has also found that lemon juice having a pH of about 2.5 containing about 30% by weight sodium saccharine can be applied to minor skin cuts substantially without the irritation normally associated with an acidic solution applied to a cut.
- the composition is an aqueous ophthalmic preparation for treating the eyes where the preparation contains an effective amount of an anti-irritant.
- the ophthalmic preparation is an aqueous solution diluted to the desired concentration with a physiological saline solution containing potassium chloride, sodium chloride and glucose.
- the ophthalmic preparation is a lactated Ringer's solution.
- the ophthalmic preparation can be administered in the form of drops to the eye to reduce the discomfort associated with dryness and to aid in the healing of injured conjunctival and corneal tissue.
- the solution can contain a suitable buffering agent, surfactant and an anti-irritant amount of a natural or non-nutritive sweetener.
- the ophthalmic solution preferably contains at least one pharmaceutical agent.
- the buffering agent is a pharmaceutically acceptable component to adjust the pH of the solution in the desired range.
- Suitable buffering agents include the combination of citric acid and a citrate. Other acids such as lactic, maleic and succinic acid can be used.
- Phosphate salts such as monosodium dihydrogenphosphate, disodium monohydrogenphosphate, monopotassium dihydrogenphosphate, dipotassium monohydrogen-phosphate, and mixtures thereof can also be used.
- the surfactants can be, for example, polyoxyalkylene derivatives such as the surfactants sold under the trademarks Tween-80, Tween-60 and Tween-40.
- the ophthalmic composition generally is adjusted to a pH of about 6.0-7.0. In further embodiments, the pH can be adjusted to below 6.0 without irritation.
- the ophthalmic preparation preferably contains about 15% to 30% by weight of a non-nutritive sweetener to serve as an anti-irritant based on the weight of the carrier.
- Sodium saccharine is the preferred anti-irritant for use in ophthalmic preparations.
- the ophthalmic preparation preferably includes a pharmaceutical agent in standard amounts commonly delivered to the eye by topical application. The preparation is generally applied to the eye or ocular cavity by applying drops to the surface of the eye.
- the ophthalmic preparation preferably includes a pharmaceutical agent or active compound commonly used in ophthalmic solutions.
- the ophthalmic solution can contain an anti-inflammatory agent, antibiotic, vasoconstrictor, antifungal, or the like, in conventional concentrations.
- the composition is an irrigating solution for use in a process of irrigating a surgical site, such as an ocular cavity or in the eye to replace the vitreous humor.
- a surgical site such as an ocular cavity or in the eye to replace the vitreous humor.
- an aqueous solution of a saccharide or disaccharide is supplied to the ocular cavity or into the eye ball to irrigate the cavity and support the eye ball during surgery.
- the aqueous solution can also include an anti-irritating amount of a synthetic sweetener.
- the surgical irrigating solution is an aqueous solution and generally contains about 15% to about 35% by weight of an artificial sweetener based on the weight of the carrier.
- the composition is an oral composition effective in removing plaque and calculus deposits from the surface of teeth.
- Calculus deposits are generally formed of calcium phosphate and calcium carbonate that adhere to the tooth surfaces and are typically associated with inflammation and bleeding of the gums. Calculus deposits are frequently a primary cause of receding gums.
- the oral composition in one embodiment of the invention is an aqueous solution containing an edible acid and an anti-irritant.
- the oral composition can be used as a mouthwash or rinse or as a dentifrice in combination with brushing or other mechanical cleaning of the teeth.
- the edible acids generally include, for example, citric acid, ascorbic acid, acetic acid, tartaric acid, maleic acid, fumaric acid, and mixtures thereof.
- the acid is included in an amount to provide a pH of less than 7.0, and generally about 2.0 to 6.0, and preferably about pH 5.5 to 6.0.
- the oral composition is fresh lemon juice.
- the oral composition has a pH of about 3.0-4.0.
- the oral composition contains a mixture of citric acid and ascorbic acid in amounts to provide a pH of less than 6.0 and generally about 5.5 to 6.0.
- the anti-irritant in the oral composition is preferably an artificial or natural sweetener.
- the preferred anti-irritant is sodium saccharine, aspartame or cyclamates, in the amount of about 15% to 30% by weight.
- the anti-irritant can be sorbitol, mannitol, xylitol, and maltitol or mixtures thereof.
- the composition further contains a mixture of an artificial sweetener and a natural sweetener. Generally, the disaccharide are less preferred for oral rinses to minimize the plaque formation.
- the oral composition can contain a flavoring agent, a fluoride source, anti-carrier agent, antibacterial agent, humectant, emulsifier, bleaching agent, surfactant or solubilizing agent.
- a flavoring agent e.g., peppermint, peppermint, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, glycerin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin
- Suitable flavoring agents include natural or synthetic flavors or oils.
- the natural flavors include citrus oils, such as lemon oil, lime oil, grapefruit oil, fruit essences, peppermint oil, spearmint oil, clove oil, bay oil, eucalyptus oil, cinnamon oil, and wintergreen oil.
- the oral composition is preferably an aqueous composition applied to the tooth surface either alone or in combination with mechanical application.
- the oral composition contains fresh lemon juice and sodium saccharine having a pH of about 2.0 to 4.0.
- This oral composition is applied to the calculus deposits with a soft dental brush or proxy brush to brush the composition onto the calculus deposits and between the teeth for a sufficient amount of time to remove or loosen the calculus deposits.
- the oral composition is applied followed by neutralizing the acid in the mouth and on the tooth surface. Neutralizing the acids can be by rinsing with water or other mouth rinse to wash and remove the acid from the tooth surfaces.
- a commercially available dentifrice, such as tooth paste can be used by brushing to neutralize and remove the acid from the tooth surfaces.
- the oral composition at a pH of about 2.0-4.0 effectively removes or loosens the calculus deposits without the need for mechanical abrasion or cleaning.
- the composition for applying directly to the tooth surfaces can include a pH adjusting agent or buffer to raise the pH to at least 5.0, and alternatively to at least pH 5.5, to reduce the effects of the acid on the enamel and dentin surfaces of the tooth.
- a suitable oral composition is an aqueous solution containing an edible acid in an amount to provide a pH of about 2.0 to 6.0, generally about pH 5.5 to 6.0, and about 20% to about 30% by weight of an anti-irritant, such as sodium saccharine.
- the oral composition can contain a physiologically acceptable alkaline agent to form a solution having a pH greater than 7.
- suitable alkaline agents include carbonates and bicarbonates such as sodium bicarbonate.
- Compositions containing sodium bicarbonate can be used as an oral rinse or an aid during the brushing of the teeth.
- the oral composition contains an artificial sweetener in an effective amount to avoid or reduce irritation to the mouth, teeth and gums.
- the carrier is a solid and the composition is in a tablet or lollipop form that can be placed in the mouth to dissolve for treating the mouth, teeth and gums.
- a tablet can be produced from a water soluble carrier containing a mixture of an acidic agent for treating of the teeth and gums, and an effective amount of an anti-irritant.
- a tablet can be formed containing an anti-inflammatory, such as aspirin, and an anti-irritant where the tablet can be chewed or swallowed. The anti-irritant reduces the irritation to the stomach normally experienced by aspirin and other bioactive compounds.
- the composition includes a water soluble carrier, an alkaline agent and an anti-irritant.
- the carrier is solid or semi-solid at room temperature that is able to release the active components and anti-irritant to the delivery area.
- suitable solid carriers included sucrose, corn syrup solids, and other confectionery compositions.
- the carrier is a lozenge, hard candy, lollipop or gel and the like comprising a mixture of a natural sweetener and an artificial sweetener such as sodium saccharine and at least one active component.
- the solid carrier is water soluble that can dissolve in the mouth to release the active agent and anti-irritant.
- Preferred natural sweeteners include sorbitol, mannitol and xylitol.
- Examples of semi-solid carriers include gels, chewing gums and other chewable compositions and compositions as known in the art.
- the carrier can be a conventional toothpaste or dentifrice gel.
- the composition is in the form of a chewing gum comprising a chewing gum base, an active component and a sweetener in an amount to provide an anti-irritant effect.
- the active component can be an analgesic, such as aspirin, acetomemophen or ibuprophen
- the anti-irritant can be an artificial sweetener, such as sodium saccharine.
- Oral compositions preferably contain an effective amount of a fluoride to treat the tooth surfaces.
- the chewing gum base of the invention can be a conventional gum base as known in art that can contain one or more solvents, plasticizer, favorants and colorants.
- the composition generally contains up to about 50% by weight of a gum base based on the total weight of the composition.
- Suitable chewing gum bases include natural and synthetic elastomers and rubbers.
- Natural chewing gum bases include natural rubber, chickle, jeluting, gutta percha and croun gum.
- Other gum bases includes rosins, such as comatone resin, pontianak resin, copel gum, kauri gum, dammar gum, sweet bay gum, spruce gum, and balsams.
- Synthetic elastomers includes butadiene-styrene copolymers, isobutylene-isoprene copolymers, polyethylene, polyisobutylene, polyvinylacetate and copolymers of vinyl acetate.
- the chewing gum includes an edible acid and an effective amount of a sweetener as an anti-irritant.
- the acid is combined with the chewing gum base in an amount to adjust the pH in the mount to about 2.0 to 6.0 and preferably about 2.0 to 5.0.
- the anti-irritant is combined with the chewing gum base in an effective amount to mask the sour taste of the acid and to provide an anti-irritant effect.
- the anti-irritant is an artificial sweetener included in an amount of about 10% to 20% by weight based on the weight of the gum base.
- the composition includes a water soluble base, an acidic component, bioactive agent and an anti-irritant in an effective amount to inhibit irritation caused by the acidic component and the bioactive agent.
- the composition is a tablet that can dissolve quickly in water.
- soluble tablets contains sodium bicarbonate, citric acid, an analgesic, such as aspirin, and saccharine.
- the composition contains an acid in an amount to form a solution of about pH 2.0 to 4.0.
- sample 1-6 were prepared from fresh lemon juice which was filtered to remove the pulp and other solid materials.
- Sample 1 was plain lemon juice with no sweeteners or additives.
- Samples 2-4 contained 3.0 ml lemon juice and sodium saccharine obtained under the trademark Sweet-N-Low in the amounts indicated in Table 1.
- Sample 5 contained 3.0 ml lemon juice and sucrose obtained as table sugar.
- Sample 6 was obtained by combining Samples 4 and 5 together. The proportions of the components and the resulting pH are indicated in Table 1 below. TABLE 1 Sample No. Vol.
- the data demonstrates that the addition of saccharine and sucrose to lemon juice does not significantly change the pH.
- the pH of each sample was measured at 25° C. from two to six times to obtain a constant measurement.
- the pH meter was calibrated the measurement of each sample.
- the saccharine of samples 4 and 6 did not completely dissolve and were presumed to be saturated solutions.
- An oral composition was prepared from 3.0 ml of fresh lemon juice and 1.0 gram of non-nutritive sweetener containing saccharine obtained under the trademark Sweet-N-Low.
- An adult male subject having calculus deposits on the subgingival and supragingival tooth surfaces applied the composition once every two days using a small proxy brush for inserting between the teeth followed by rinsing with the oral composition.
- the patient reported no irritation, burning or discomfort to the gum surfaces or to the teeth normally associated with an acidic solution when applied to the gums and tooth surfaces. After two weeks, significant reduction in the calculus depositions on the teeth were observed and the remaining calculus deposits easily separated from the tooth surface by the use of a dental tool.
- a topical composition was prepared from about 3.0 ml fresh lemon juice and 1.0 g of a sweetener containing sodium saccharine obtained under the trademark Sweet-N-Low. The resulting solution was applied to a scratch on the skin of an adult male patient. The patient reported substantially no irritation or burning of the scratch.
- Example 3 The composition of Example 3 was applied to the surface of the eye of an adult male patient. The patient reported no burning or irritation in the eye.
- a composition can be prepared from a chewing gum base, ascorbic acid as an active component, and sodium saccharine as an anti-irritant.
- the composition contains about 5.0% by weight ascorbic acid and about 10.0% by weight sodium saccharine based on the weight of the composition.
- the composition is administered by chewing to disperse the ascorbic acid and sodium saccharine to the surfaces of the patient's teeth for sufficient to treat the tooth surfaces.
- the ascorbic acid and the chewing action assist in removing calculus deposits from the tooth surfaces while the sodium saccharine provides an anti-irritant effect on the tooth and gum surfaces.
- a composition is prepared from a sorbitol base to form a hard candy.
- the composition contains about 5.0% citric acid, acetic acid, ascorbic acid and mixtures thereof in an amount to adjust the pH of the saliva to about pH 4.0 to 6.0 when placed in the mouth.
- the composition also contains about 10.0% by weight sodium saccharine based on the weight of the composition to inhibit irritation to the tooth and gum surfaces.
- the composition is administered by placing in the mouth to dissolve the carrier and disperse the acid and anti-irritant.
- the carrier dissolves at a rate to provide a sustained release of the active component and anti-irritant.
- a tablet is prepared from sorbitol as a carrier material, aspirin and about 10% by weight sodium saccharine.
- the tablet is administered orally and is swallowed whole by the patient to administer the aspirin to the patient.
- the patient experiences less stomach irritation than that experienced by patients when the anti-irritant is not used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition and process for suppressing pain and irritation of tissue includes an anti-irritant in an effective amount to suppress pain and irritation temporarily when applied topically to the skin or mucosa. The anti-irritant is a natural or non-nutritive sweetener. The composition can be a solid containing an edible acid such as citric acid and ascorbic acid from fresh lemon juice to form a solution having a pH of about 2.0 to 4.0 and an anti-irritant, such as sodium saccharine. The composition can be used to apply a pharmaceutical agent to the skin, mucosa or eye without irritation. The acidic composition can further be used to remove or loosen calculus deposits from the teeth without burning or irritation of the gums.
Description
- This application is a continuation-in-part of application Ser. No. 340,111, filed Jun. 28, 1999 by Peyman and is hereby incorporated by reference in its entirety.
- The present invention is directed to a process and composition for treating the surface of the skin or other tissue with an active compound substantially without irritation. More particularly, the invention is directed to a process and composition for suppressing pain topically on the eye, skin or mucosa tissue.
- Many substances are commonly applied to the skin, mucosa tissue and to other tissue of humans and animals to treat the surface of the skin or tissue. Typical examples of compositions that are applied to the skin include cosmetics, sunscreens and the like. Other compositions often include a pharmaceutical agent such as an antibiotic or bactericide for treating the surface of the tissue.
- Topically applied compositions are generally in the form of liquids, creams, lotions and gels. In many instances, the compositions that are applied topically contain various components, which inherently cause irritation and inflammation when applied to the skin or the mucosa. The occurrence and frequency of the irritation can vary depending on the person, the specific components in the composition and the various components present.
- Common symptoms of irritation from topically applied compositions include itching, stinging, burning, tingling, tightness, redness and swelling. The irritation can be due to the direct effect on the skin or the mucosa of the active ingredient or the carrier or in response to the immune system directly toward the chemicals alone or in combination with the skin components.
- Many ingredients used in topically applied products are known irritants or are potentially irritating, especially for certain people with some allergies or sensitivities. Ingredients which can act as irritants include solvents, fragrances, preservatives, propellants, and pharmaceutical agents. Examples of common topical compositions, which can cause irritation, include exfolients and skin renewal agents, antiperspirants, antihistamines, anti-inflammatory agents, skin protective agents, insect repellants and sunscreens. Where more than one irritant compound is present, the effects can be additive. In addition, various components can interact with each other to cause irritation which might not occur when used alone.
- Various efforts have been proposed to attempt to find methods and compositions for reducing or eliminating irritation caused by the topical application of various compositions. For example, one such method attempts to reduce the irritation caused by hydroxy acids and keto-acids in topically applied products by adding a strong alkali base metal such as sodium or potassium hydroxide. The effect of the hydroxide is to raise the pH and to reduce the acidity of the composition. However, this approach has the disadvantage of reducing the effectiveness of the hydroxy acid to penetrate the skin and to reduce the effectiveness of the acid. Other hydroxides and organic amines have also been proposed to adjust the pH of the composition. However, raising the pH using these bases also reduces the effectiveness of the composition.
- A further example of methods reducing irritation caused by topically applied compositions is disclosed ion U.S. Pat. No. 5,716,625 to Hahn. This patent discloses the use of a strontium metal cation to reduce irritation. It is proposed that the cation interacts with the epidermis nerve cells to prevent or counteract the sensation of irritation by interfering with the irritation inducing components of the skin cells. The strontium cation is proposed to alter the ability of the epidermal cells to depolarize by blocking or interfering with ion channel or pump operation or by altering the transmembranal action potential. It has also been proposed that the strontium cation acts to inhibit or modify the action of skin cell protease or other irritation inducing components.
- The human skin and mucosa tissue presents a complicated structural and sensory environment. The skin contains nerves and highly specific sensory cells that are specialized. These cells are developed to differentiate the stimuli leading to specific sensation such as pain. In addition, nerves in the skin are responsive to native or foreign chemicals such as proteases, prostaglandins, complement system molecules, allergens and the like. Agents that are effective in combating one stimulus are often ineffective against another stimulus.
- Many pharmaceutical agents when applied topically produce a burning sensation, especially when applied to a cut or sensitive tissue. For example, various eye drops containing a pharmaceutical agent when applied to the eye result in a painful burning of the eye.
- Accordingly, there is a continuing need in the industry for a method of reducing or eliminating the pain associated with the topical application of various components.
- The present invention is directed to a process and composition for inhibiting pain and irritation that is normally caused by topically applying a bioactive agent or medicament. More particularly, the invention is directed to a process for treating tissue with a liquid or solid composition and temporarily suppressing pain of the tissue being treated.
- Accordingly, a primary object of the invention is to provide a process for treating skin or mucosa tissue with a composition where the composition contains an active ingredient and an effective amount of an anti-irritant.
- Another object of the invention is to provide a process for treating tissue by contacting said tissue with a composition comprising a water soluble carrier, an effective amount of a bioactive agent, and anti-irritant to temporarily suppress pain and irritation of the tissue.
- A still further object of the invention is to provide a process for topically treating mucosa with a water soluble solid composition containing a pharmaceutical agent and an effective amount of an anti-irritant.
- Another object of the invention is to provide a process for temporarily suppressing pain and irritation by topically applying a solid composition containing an effective amount of an anti-irritant.
- A further object of the invention is to provide a process and composition for removing calculus from tooth surfaces substantially without irritation to the gums and the tooth by applying a solid composition containing an acidic or alkaline material and an effective amount of an anti-irritant.
- Another object of the invention is to provide a solid composition containing an active component for applying topically to the skin or mucosa, where the composition contains a pain suppressing amount of saccharine.
- A further object of the invention is to provide a process for topically treating skin or mucosa with a water soluble solid composition capable of forming a solution having a pH of about 4.0 or less and a pain and irritation suppressing amount of a synthetic sweetener.
- The objects and advantages of the invention are basically attained by providing a process for treating tissue of an animal with at least one bioactive compound by providing a water soluble composition comprising, at least one bioactive compound and at least one sweetener. The sweetener is included in an effective amount to block pain receptors temporarily in animal tissue upon release from the composition. The composition is applied to the tissue of the animal in an effective amount to treat the tissue with the bioactive compound and to suppress pain and irritation of the tissue.
- The objects of the invention are further attained by providing a process for removing calculus and other deposits from the surface of the teeth of an animal comprising the steps of: providing a water soluble composition containing an edible acid in an amount to form a solution having a pH of about 6.0 or less and at least one sweetener in an amount to suppress irritation of gum tissue. The water soluble composition is placed in the mouth or applied to the surfaces of the teeth for an effective amount of time to substantially remove calculus and deposits from the teeth.
- The objects and advantages of the invention are also attained by providing a process for temporarily suppressing pain receptors and reducing irritation of the tissue of an animal comprising the steps of: providing a solid or semi-solid carrier, at least one water soluble or water dispersible bioactive compound and at least one sweetener. The sweetener is present in an effective amount to suppress the pain receptors of the tissue and to reduce pain and irritation to the tissue caused by the composition. The tissue is contacted with the bioactive compound in an amount to treat the tissue with the bioactive compound substantially without irritation to the tissue.
- The objects of the invention are further attained by providing a composition comprising a solid or semi-solid carrier, at least one bioactive component and a pain and irritation suppressing amount of a non-nutritive sweetener.
- The objects, advantages and other salient features of the invention will become apparent from the following detailed description of the invention.
- The present invention is directed to a process and composition for temporarily suppressing pain and irritation by applying an effective amount of an anti-irritant to the skin, mucosa, eye or other tissue. More particularly, the invention is directed to a process and composition for topically delivering a composition to a specific site on a patient where the composition contains an anti-irritant in an amount to inhibit irritation to the delivery site.
- The composition of the invention in preferred embodiments contains at least one active component such as a biologically active agent, a suitable vehicle or carrier, and an anti-irritant. The carrier can be a liquid, solid or semi-solid. In various embodiments, the composition is an aqueous solution. Alternatively, the composition can be a dispersion, emulsion, gel, lotion or cream containing a vehicle for the various components. In one embodiment, the primary vehicle is water. The liquid vehicle can include other materials, such as alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired consistency and viscosity.
- The composition that is applied to the treatment site can be a liquid or solid depending on the treatment site. For example, the composition can include a solid or semi-solid carrier when the composition is used as a lozenge or tablet for the oral delivery of an active component. In further embodiments the composition can be used as an implant or a suppository. Liquid carriers are desirable in some instances for oral use, such as mouth washes, gargle solutions and the like. Liquid carriers are also desirable for irrigation solutions for irrigating a cut, wound or surgical site, such as during surgical removal of a tumor and irrigating the bladder or vagina.
- The invention is primarily directed to a composition containing an anti-irritant agent in an effective amount that is capable of suppressing the pain receptors in the tissue to inhibit pain and irritation to the area being treated topically with the composition. The invention is further directed to a process of treating tissue or applying an active agent to an area with little or no irritation. It has been found that various natural and particularly artificial or synthetic non-nutritive sweeteners are able to provide a temporary suppression of pain and irritation to the area being treated when applied topically. In particular, it has been found that compositions using an artificial, non-nutritive sweetener in amounts in excess of the amounts conventionally used for sweetening a food product have an anti-irritant effect. Although not completely understood, it is believed that the natural sweeteners and particularly the synthetic, non-nutritive sweeteners are able to block the pain receptors at the site on the tissue being treated. Patients using the compositions of the invention, when applied topically to skin, mucosa, and other tissue, experience a reduction in pain and irritation than would otherwise occur and without numbness or loss of feeling to the treated area.
- In preferred embodiments of the invention, the anti-irritant is an artificial non-nutritive sweetener included in the composition in an effective amount to suppress or inhibit pain and inhibit irritation caused by topically applying the composition to the skin, mucosa or other tissue. The artificial, non-nutritive sweetener can be a commercially available sweetener such as saccharine and the salts thereof, aspartame, cyclamates and the salts thereof, acetesulfone K, and mixtures thereof. In preferred embodiments, the non-nutritive sweetener is sodium saccharine obtained commercially as a food sweetener, such as the product available under the trademark Sweet-N-Low. The commercially available food sweeteners typically include a bulking and dispersing component such as dextrose. The bulking and dispersing components of the commercial sweeteners do not interfere with the anti-irritant effect of the sweetener. Sodium saccharine is generally preferred since it is readily soluble in water and readily available.
- In further embodiments, the anti-irritant is a natural sweetener such as a monosaccharide, disaccharide or polysaccharide. Suitable natural monosaccharide sweeteners include glucose and fructose. Other sweeteners include, arabinose, xylose, ribose, mannose, galactose, dextrose, sorbose, sorbitol, mannitol, and mixtures thereof. Suitable disaccharides include, sucrose, lactose, maltose and cellobiose. The polysaccharides can include partially hydrolyzed starch, dextrin, stevioside or corn syrup salts. In embodiments of the invention, the natural sweeteners can be used in combination with one or more non-nutritive sweeteners. Other suitable sweeteners include sorbitol, mannitol, xylitol and the like.
- The composition of the invention includes a carrier capable of delivering the anti-irritant and the active ingredient. Generally, the preferred liquid carrier is water, although other pharmaceutically acceptable carriers can be used depending on the intended use of the composition. The carrier can include various co-solvents, dispersing agents or emulsifiers as known in the art. In one embodiment, the carrier is water substantially in the absence of emulsifiers or dispersing agents. Alternatively, the carrier can also contain various thickening or gelling agents to obtain the desired consistency or viscosity.
- In embodiments of the invention, the vehicle for topical application to the skin can include various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials. The vehicles used for compositions for treating mucosa are limited primarily by the toxicity of the vehicle to the tissue.
- The anti-irritant is preferably dissolved or dispersed in the liquid carrier in an amount to provide the desired anti-irritant effect. The amount of the anti-irritant will depend on the particular anti-irritant being used, and the active ingredient responsible for the irritation since some active ingredients are more likely to cause irritation. The sensitivity of the intended tissue being treated also determines the amount of the anti-irritant in the composition.
- In one embodiment of the invention, the anti-irritant is an artificial sweetener. A particularly suitable sweetener is the commercially available sodium saccharine. The sodium saccharine is included in the amount of about 10% to about 40% by weight based on the total weight of the carrier. The amount of the non-nutritive can vary depending on the other components of the composition. Generally, the non-nutritive sweetener is used in similar amounts for liquid and solid carriers. Generally, the sodium saccharine is included in the amount of 15% to about 30% by weight based on the total weight of the carrier. Commercially available saccharine products sold as ready-to-use sugar substitutes contain about 60% by weight saccharine, with the remaining amount being made up of dextrose and other bulking, dispersing and anti-caking agents. These commercially available sodium saccharine products are used in amounts, typically about 25% to 35% by weight, to provide the desired saccharine concentrations in the final product. Other artificial non-nutritive sweeteners such as aspartame and cyclamates and salts thereof are used in similar amounts as the saccharine. In further embodiments, the artificial non-nutritive sweetener is included in an amount to form a saturated solution.
- The natural sweeteners, such as sucrose, can be included in the composition in the amount of about 15% to 30% by weight based on the total weight of the composition. Generally, when the carrier is a liquid the natural sweetener forms a saturated or near saturated solution. In preferred embodiments, the anti-irritant is an artificial non-nutritive sweetener to avoid the stickiness associated with topical applications of natural sweeteners. In still further embodiments the composition is an aqueous medium containing a mixture of a natural sweetener, such as sucrose or sorbitol, and an anti-irritant amount of a synthetic sweetener such as sodium saccharine.
- The composition also contains an active compound which can be at least one bioactive ingredient in an amount to provide effective treatment of the patient in need thereof. The bioactive ingredient can be, for example, an antifungal, anti-inflammatory, antibiotic, analgesic, immunosuppressive agent, and mixtures thereof. The anti-inflammatory agents can be steroidal, non-steroidal or salicylates. Examples of anti-inflammatory agents include acetylsalicylic acid (aspirin), ibuprofen and acetaminophen. The suitable antibiotics can include aminoglycosides, cephalosporins, macrolides, monobactrams, penicillins, quinolines, sulfonamides and tetracyclines as known in the art. Examples of immunosuppressive agents include cyclosporin, azathioprine and Rho(D)immune globulin. These active ingredients are intended to be exemplary of suitable pharmaceutically active components. It will be understood that other bioactive ingredients can be used that are capable of inducing a desired response or treating a particular condition. The amounts of the active compounds in the composition are standard concentrations for topically applied components as known in the art.
- In further embodiments, the composition includes a pharmaceutically acceptable or edible acid to adjust the pH below 7.0, and generally below about pH 6.0. Suitable acids include, for example, citric acid, acetic acid, ascorbic acid, malic acid, adipic acid, fumaric acid, and mixtures thereof. In embodiments of the invention, the acid functions as a bioactive compound for certain topical applications. In preferred embodiments, the acid is in the form of a citrus juice from lemons, limes, oranges, grapefruits, tangerines, tangelos, and mixtures thereof Generally, the citrus juice is fresh squeezed juice or juice obtained from reconstituted concentrate. The most preferred citrus juice is fresh lemon juice. In further embodiments, the composition can contain a mixture of citric acid and ascorbic acid.
- In embodiments of the invention, the acid, which can be a citrus juice, is included in an amount to provide a solution having a pH of about 2.0-6.0, depending on the desired pH for the tissue being treated. In embodiments, the composition has a pH of about 2.0-3.0 for some topical applications to the skin and mucosa. Fresh lemon juice, for example, typically has a pH of about 2.3 to 2.4. In embodiments where the carrier is a liquid, the acid compound is included in an amount to produce a solution having a pH of about 2.0-6.0, and preferably a pH of about 2.0-5.0.
- Acidic agents are known generally to produce a burning and irritating effect when applied to sensitive tissue such as scratches or cuts on the skin, mucosa and the eye. It has been found that the anti-irritants of the invention, and particularly sodium saccharine, has an anti-irritant effect on tissue to inhibit the irritation caused by the acid added in an effective amount. Moreover, pH measurements of acid solutions containing varying amounts of sucrose and/or sodium saccharine have shown that the sucrose and sodium saccharine do not significantly alter the pH of the acidic solution. One aspect of the invention is based on the use of an anti-irritant agent without significantly adjusting the pH of the acidic solution.
- In embodiments of the invention, the pH of the composition is adjusted as necessary to dissolve a desired active compound. For example, certain compounds are stable or soluble only in acid or alkaline solutions and cannot be easily dissolved without adjusting the pH. The anti-irritant of the invention enables the use of acidic or alkaline solutions containing compounds that are insoluble or unstable at neutral pH without irritation normally associated with acidic or alkaline solutions. In one embodiment, acid solutions having a pH of less than about 5.0 can be applied to the skin or mucosa tissue substantially without irritation.
- The composition in one form of the invention is an aqueous solution containing an active ingredient for applying topically to the skin, mucosa, or other tissue. Compositions for applying topically to the tissue preferably contain an antibiotic, antibacterial agent, analgesic or anti-inflammatory, and an anti-irritating amount of a natural or artificial sweetener. The composition is particularly suitable for treating minor cuts, scratches, and abrasions on the skin substantially without irritation. It has been found that an aqueous solution containing 25% to 35% by weight sodium saccharine and an acid, such as ascorbic, citric or acetic acid to produce a solution having a pH of about 2.5-3.0, can be applied to scratches and minor cuts on the skin substantially without irritation. The sodium saccharine is believed to provide a temporary suppression of the nerve endings on the skin to prevent or reduce the irritation. It has also found that lemon juice having a pH of about 2.5 containing about 30% by weight sodium saccharine can be applied to minor skin cuts substantially without the irritation normally associated with an acidic solution applied to a cut.
- In a further embodiment, the composition is an aqueous ophthalmic preparation for treating the eyes where the preparation contains an effective amount of an anti-irritant. Generally, the ophthalmic preparation is an aqueous solution diluted to the desired concentration with a physiological saline solution containing potassium chloride, sodium chloride and glucose. In further embodiments, the ophthalmic preparation is a lactated Ringer's solution. The ophthalmic preparation can be administered in the form of drops to the eye to reduce the discomfort associated with dryness and to aid in the healing of injured conjunctival and corneal tissue. The solution can contain a suitable buffering agent, surfactant and an anti-irritant amount of a natural or non-nutritive sweetener. The ophthalmic solution preferably contains at least one pharmaceutical agent.
- The buffering agent is a pharmaceutically acceptable component to adjust the pH of the solution in the desired range. Suitable buffering agents include the combination of citric acid and a citrate. Other acids such as lactic, maleic and succinic acid can be used. Phosphate salts such as monosodium dihydrogenphosphate, disodium monohydrogenphosphate, monopotassium dihydrogenphosphate, dipotassium monohydrogen-phosphate, and mixtures thereof can also be used. The surfactants can be, for example, polyoxyalkylene derivatives such as the surfactants sold under the trademarks Tween-80, Tween-60 and Tween-40. The ophthalmic composition generally is adjusted to a pH of about 6.0-7.0. In further embodiments, the pH can be adjusted to below 6.0 without irritation.
- The ophthalmic preparation preferably contains about 15% to 30% by weight of a non-nutritive sweetener to serve as an anti-irritant based on the weight of the carrier. Sodium saccharine is the preferred anti-irritant for use in ophthalmic preparations. The ophthalmic preparation preferably includes a pharmaceutical agent in standard amounts commonly delivered to the eye by topical application. The preparation is generally applied to the eye or ocular cavity by applying drops to the surface of the eye. The ophthalmic preparation preferably includes a pharmaceutical agent or active compound commonly used in ophthalmic solutions. For example, the ophthalmic solution can contain an anti-inflammatory agent, antibiotic, vasoconstrictor, antifungal, or the like, in conventional concentrations.
- In a further form of the invention, the composition is an irrigating solution for use in a process of irrigating a surgical site, such as an ocular cavity or in the eye to replace the vitreous humor. For example, during ocular surgery, an aqueous solution of a saccharide or disaccharide is supplied to the ocular cavity or into the eye ball to irrigate the cavity and support the eye ball during surgery. The aqueous solution can also include an anti-irritating amount of a synthetic sweetener. The surgical irrigating solution is an aqueous solution and generally contains about 15% to about 35% by weight of an artificial sweetener based on the weight of the carrier.
- In a further embodiment of the invention, the composition is an oral composition effective in removing plaque and calculus deposits from the surface of teeth. Calculus deposits are generally formed of calcium phosphate and calcium carbonate that adhere to the tooth surfaces and are typically associated with inflammation and bleeding of the gums. Calculus deposits are frequently a primary cause of receding gums.
- The oral composition in one embodiment of the invention is an aqueous solution containing an edible acid and an anti-irritant. The oral composition can be used as a mouthwash or rinse or as a dentifrice in combination with brushing or other mechanical cleaning of the teeth. The edible acids generally include, for example, citric acid, ascorbic acid, acetic acid, tartaric acid, maleic acid, fumaric acid, and mixtures thereof. The acid is included in an amount to provide a pH of less than 7.0, and generally about 2.0 to 6.0, and preferably about pH 5.5 to 6.0. In a preferred embodiment, the oral composition is fresh lemon juice. In an embodiment, the oral composition has a pH of about 3.0-4.0. In further embodiments, the oral composition contains a mixture of citric acid and ascorbic acid in amounts to provide a pH of less than 6.0 and generally about 5.5 to 6.0.
- The anti-irritant in the oral composition is preferably an artificial or natural sweetener. The preferred anti-irritant is sodium saccharine, aspartame or cyclamates, in the amount of about 15% to 30% by weight. Alternatively, the anti-irritant can be sorbitol, mannitol, xylitol, and maltitol or mixtures thereof. The composition further contains a mixture of an artificial sweetener and a natural sweetener. Generally, the disaccharide are less preferred for oral rinses to minimize the plaque formation. In further embodiments, the oral composition can contain a flavoring agent, a fluoride source, anti-carrier agent, antibacterial agent, humectant, emulsifier, bleaching agent, surfactant or solubilizing agent. Although the oral composition is preferably an aqueous solution, the solution can contain up to 20% by weight of a cosolvent, such as ethyl alcohol.
- Suitable flavoring agents include natural or synthetic flavors or oils. The natural flavors include citrus oils, such as lemon oil, lime oil, grapefruit oil, fruit essences, peppermint oil, spearmint oil, clove oil, bay oil, eucalyptus oil, cinnamon oil, and wintergreen oil.
- In embodiments of the invention, the oral composition is preferably an aqueous composition applied to the tooth surface either alone or in combination with mechanical application. In one embodiment of the invention, the oral composition contains fresh lemon juice and sodium saccharine having a pH of about 2.0 to 4.0. This oral composition is applied to the calculus deposits with a soft dental brush or proxy brush to brush the composition onto the calculus deposits and between the teeth for a sufficient amount of time to remove or loosen the calculus deposits. Generally, the oral composition is applied followed by neutralizing the acid in the mouth and on the tooth surface. Neutralizing the acids can be by rinsing with water or other mouth rinse to wash and remove the acid from the tooth surfaces. Alternatively, a commercially available dentifrice, such as tooth paste, can be used by brushing to neutralize and remove the acid from the tooth surfaces.
- Typically, the oral composition at a pH of about 2.0-4.0 effectively removes or loosens the calculus deposits without the need for mechanical abrasion or cleaning. The composition for applying directly to the tooth surfaces can include a pH adjusting agent or buffer to raise the pH to at least 5.0, and alternatively to at least pH 5.5, to reduce the effects of the acid on the enamel and dentin surfaces of the tooth.
- Regular cleaning of the tooth surfaces with the oral composition has shown to remove substantial amounts of calculus deposits on the teeth and to loosen the deposits. In some instances, the calculus deposits are completely removed. In other instances, the deposits are loosened so that they can be easily removed by a dentist or hygienist during routine cleaning by mechanical action. The composition is also found to be effective in preventing or reducing the amount of the calculus deposits which normally form on the teeth. A suitable oral composition is an aqueous solution containing an edible acid in an amount to provide a pH of about 2.0 to 6.0, generally about pH 5.5 to 6.0, and about 20% to about 30% by weight of an anti-irritant, such as sodium saccharine.
- In a further embodiment, the oral composition can contain a physiologically acceptable alkaline agent to form a solution having a pH greater than 7. Examples of suitable alkaline agents include carbonates and bicarbonates such as sodium bicarbonate. Compositions containing sodium bicarbonate can be used as an oral rinse or an aid during the brushing of the teeth. In preferred embodiments, the oral composition contains an artificial sweetener in an effective amount to avoid or reduce irritation to the mouth, teeth and gums.
- In another embodiment, the carrier is a solid and the composition is in a tablet or lollipop form that can be placed in the mouth to dissolve for treating the mouth, teeth and gums. For example, a tablet can be produced from a water soluble carrier containing a mixture of an acidic agent for treating of the teeth and gums, and an effective amount of an anti-irritant. Alternatively, a tablet can be formed containing an anti-inflammatory, such as aspirin, and an anti-irritant where the tablet can be chewed or swallowed. The anti-irritant reduces the irritation to the stomach normally experienced by aspirin and other bioactive compounds. In further embodiments the composition includes a water soluble carrier, an alkaline agent and an anti-irritant.
- In embodiments of the invention, the carrier is solid or semi-solid at room temperature that is able to release the active components and anti-irritant to the delivery area. In embodiments of the invention, suitable solid carriers included sucrose, corn syrup solids, and other confectionery compositions. In embodiments, the carrier is a lozenge, hard candy, lollipop or gel and the like comprising a mixture of a natural sweetener and an artificial sweetener such as sodium saccharine and at least one active component. Preferably, the solid carrier is water soluble that can dissolve in the mouth to release the active agent and anti-irritant. Preferred natural sweeteners include sorbitol, mannitol and xylitol.
- Examples of semi-solid carriers include gels, chewing gums and other chewable compositions and compositions as known in the art. The carrier can be a conventional toothpaste or dentifrice gel. In one embodiment of the invention, the composition is in the form of a chewing gum comprising a chewing gum base, an active component and a sweetener in an amount to provide an anti-irritant effect. The active component can be an analgesic, such as aspirin, acetomemophen or ibuprophen, and the anti-irritant can be an artificial sweetener, such as sodium saccharine. Oral compositions preferably contain an effective amount of a fluoride to treat the tooth surfaces.
- The chewing gum base of the invention can be a conventional gum base as known in art that can contain one or more solvents, plasticizer, favorants and colorants. The composition generally contains up to about 50% by weight of a gum base based on the total weight of the composition. Suitable chewing gum bases include natural and synthetic elastomers and rubbers. Natural chewing gum bases include natural rubber, chickle, jeluting, gutta percha and croun gum. Other gum bases includes rosins, such as comatone resin, pontianak resin, copel gum, kauri gum, dammar gum, sweet bay gum, spruce gum, and balsams. Synthetic elastomers includes butadiene-styrene copolymers, isobutylene-isoprene copolymers, polyethylene, polyisobutylene, polyvinylacetate and copolymers of vinyl acetate.
- In embodiments of the invention, the chewing gum includes an edible acid and an effective amount of a sweetener as an anti-irritant. The acid is combined with the chewing gum base in an amount to adjust the pH in the mount to about 2.0 to 6.0 and preferably about 2.0 to 5.0. The anti-irritant is combined with the chewing gum base in an effective amount to mask the sour taste of the acid and to provide an anti-irritant effect. Generally, the anti-irritant is an artificial sweetener included in an amount of about 10% to 20% by weight based on the weight of the gum base.
- In a further embodiment of the invention, the composition includes a water soluble base, an acidic component, bioactive agent and an anti-irritant in an effective amount to inhibit irritation caused by the acidic component and the bioactive agent. Typically, the composition is a tablet that can dissolve quickly in water. Preferably, the acidic component included in an effective amount to produce a pH of about 2.0 to 5.0 and includes an artificial sweetener in an amount to inhibit irritation caused by the acid. One example of soluble tablets contains sodium bicarbonate, citric acid, an analgesic, such as aspirin, and saccharine. In one embodiment, the composition contains an acid in an amount to form a solution of about pH 2.0 to 4.0.
- The following non-limiting examples of the invention demonstrate various embodiments of the invention.
- This example demonstrates that sodium saccharine and sucrose have little effect on the pH of an aqueous composition of the invention. In this example, the samples 1-6 were prepared from fresh lemon juice which was filtered to remove the pulp and other solid materials. Sample 1 was plain lemon juice with no sweeteners or additives. Samples 2-4 contained 3.0 ml lemon juice and sodium saccharine obtained under the trademark Sweet-N-Low in the amounts indicated in Table 1. Sample 5 contained 3.0 ml lemon juice and sucrose obtained as table sugar. Sample 6 was obtained by combining Samples 4 and 5 together. The proportions of the components and the resulting pH are indicated in Table 1 below.
TABLE 1 Sample No. Vol. of Lemon Juice Anti-Irritant pH 1 3.0 ml none 2.36 2 3.0 ml 1.0699 g saccharine 2.25 3 3.0 ml 1.9066 g saccharine 2.23 4 3.0 ml 2.888 g saccharine 2.35 5 3.0 ml 3.3254 g sugar 2.17 6 3.0 ml 3.3254 g sugar 2.888 g saccharine 2.24 - The data demonstrates that the addition of saccharine and sucrose to lemon juice does not significantly change the pH. The pH of each sample was measured at 25° C. from two to six times to obtain a constant measurement. The pH meter was calibrated the measurement of each sample. The saccharine of samples 4 and 6 did not completely dissolve and were presumed to be saturated solutions.
- An oral composition was prepared from 3.0 ml of fresh lemon juice and 1.0 gram of non-nutritive sweetener containing saccharine obtained under the trademark Sweet-N-Low. An adult male subject having calculus deposits on the subgingival and supragingival tooth surfaces applied the composition once every two days using a small proxy brush for inserting between the teeth followed by rinsing with the oral composition. The patient reported no irritation, burning or discomfort to the gum surfaces or to the teeth normally associated with an acidic solution when applied to the gums and tooth surfaces. After two weeks, significant reduction in the calculus depositions on the teeth were observed and the remaining calculus deposits easily separated from the tooth surface by the use of a dental tool.
- A topical composition was prepared from about 3.0 ml fresh lemon juice and 1.0 g of a sweetener containing sodium saccharine obtained under the trademark Sweet-N-Low. The resulting solution was applied to a scratch on the skin of an adult male patient. The patient reported substantially no irritation or burning of the scratch.
- The composition of Example 3 was applied to the surface of the eye of an adult male patient. The patient reported no burning or irritation in the eye.
- A composition can be prepared from a chewing gum base, ascorbic acid as an active component, and sodium saccharine as an anti-irritant. The composition contains about 5.0% by weight ascorbic acid and about 10.0% by weight sodium saccharine based on the weight of the composition. The composition is administered by chewing to disperse the ascorbic acid and sodium saccharine to the surfaces of the patient's teeth for sufficient to treat the tooth surfaces. The ascorbic acid and the chewing action assist in removing calculus deposits from the tooth surfaces while the sodium saccharine provides an anti-irritant effect on the tooth and gum surfaces.
- A composition is prepared from a sorbitol base to form a hard candy. The composition contains about 5.0% citric acid, acetic acid, ascorbic acid and mixtures thereof in an amount to adjust the pH of the saliva to about pH 4.0 to 6.0 when placed in the mouth. The composition also contains about 10.0% by weight sodium saccharine based on the weight of the composition to inhibit irritation to the tooth and gum surfaces. The composition is administered by placing in the mouth to dissolve the carrier and disperse the acid and anti-irritant. The carrier dissolves at a rate to provide a sustained release of the active component and anti-irritant.
- A tablet is prepared from sorbitol as a carrier material, aspirin and about 10% by weight sodium saccharine. The tablet is administered orally and is swallowed whole by the patient to administer the aspirin to the patient. The patient experiences less stomach irritation than that experienced by patients when the anti-irritant is not used.
- While various embodiments have been chosen to illustrate the invention, it will be understood by those skilled in the art that various modifications can be made without departing from the spirit and scope of the invention as defined in the following claims.
Claims (33)
1. A process for treating tissue of an animal with at least one bioactive compound comprising the steps of:
providing a composition comprising a solid carrier containing at least one bioactive compound and at least one anti-irritant in an effective amount to block pain receptors temporarily in animal tissue, wherein said anti-irritant is a natural or artificial sweetener; and
orally administering said solid composition to release in an effective amount of said bioactive compound and anti-irritant for sufficient time to treat said tissue with said bioactive compound and to suppress pain and irritation of said tissue.
2. The process of claim 1 , wherein said composition is an oral composition and said tissue being treated is in the mouth.
3. The process of claim 1 , wherein said at least one bioactive compound is a pharmaceutically active compound selected from the group consisting of analgesics, antibiotics, antibacterial agents, immunosuppressive agent, antifungal agent and anti-inflammatory agents.
4. The process of claim 1 , wherein said bioactive compound is selected from the group consisting of salicylic acid acetate, acetamenophen and ibuprofen.
5. The process of claim 1 , wherein said sweetener is selected from the group consisting of saccharin, aspartame, cyclamates, and salts thereof.
6. The process of claim 1 , wherein said bioactive compound is organic acid in an amount to provide a solution having a pH of less than 6.0.
7. The process of claim 6 , wherein said organic acid is included in an amount to provide a solution having a pH of about 2.0 to 5.0.
8. The process of claim 1 , wherein said composition is water soluble and said process comprises contacting said composition with body fluids to release said bioactive compound and anti-irritant.
9. The process of claim 6 , wherein said organic acid is selected from the group consisting of citric acid, acetic acid, ascorbic acid, malic acid, adipic acid, fumaric acid, and mixtures thereof.
10. The process of claim 1 , wherein said composition comprises citric acid in an amount to form a pH of about 2.0 to 4.0 and said sweetener is saccharin in an amount to suppress pain receptors temporarily on the tissue being treated.
11. The process of claim 1 , wherein said bioactive compound is an alkaline material.
12. The process of claim 11 , wherein said anti-irritant is an artificial sweetener and said composition comprises about 10% to about 3.0% by weight of said artificial sweetener.
13. The process of claim 1 , wherein said carrier is a gum base or a water soluble base.
14. A process for removing calculus and other deposits from the surface of the teeth of an animal comprising the steps of:
providing a composition comprising solid carrier containing an edible acid in an amount to form a solution having a pH of about 6.0 or less and at least one anti-irritant in an amount to suppress irritation of gum tissue, wherein said anti-irritant is a natural or artificial sweetener, and
placing the composition in the mouth of a patient to disperse said acid and anti-irritant to the surfaces of the teeth for an effective amount of time to substantially remove or loosen calculus and deposits from the teeth without irritation to the gums.
15. The process of claim 14 , wherein said carrier comprises an anti-irritant amount of an artificial sweetener selected from the group consisting of sodium saccharine, aspartame and cyclamates, wherein said artificial sweetener is included in the amount of about 10% to 30% by weight based on the total weight of the composition.
16. The process of claim 14 , wherein said composition further comprises an anti-bacterial agent.
17. The process of claim 14 , wherein said carrier comprises a natural sweetener selected from the group consisting of sorbitol, mannitol, and xylitol and a non-nutritive sweetener selected from the group consisting of saccharin, aspartame, and cyclamates.
18. The process of claim 14 , wherein said aqueous composition comprises an organic acid in an amount to form a solution having a pH of less than 5.0.
19. The process of claim 14 , wherein said carrier is a chewing gum base or a water soluble base.
20. The process of claim 14 , wherein said edible acid is selected from the group consisting of citric acid, acetic acid, ascorbic acid, malic acid, adipic acid, fumaric acid, and mixtures thereof.
21. The process of claim 14 , wherein said composition comprises ascorbic acid and citric acid in an amount to form a solution having a pH of about 2.0 to 5.0 and said sweetener is sodium saccharin in an amount to suppress pain receptors temporarily on the gums.
22. A process for temporarily suppressing pain receptors and inhibiting pain and irritation of the tissue of an animal comprising the steps of:
providing a composition comprising a solid carrier, at least one bioactive agent and at least one anti-irritant, said anti-irritant being a natural sweetener or non-nutritive sweetener in an effective amount to suppress the pain receptors of the tissue and to reduce pain and irritation to the tissue caused by said composition, and
contacting said tissue and body fluids of said tissue with said composition to disperse said bioactive agent and anti-irritant in an amount to treat said tissue with said bioactive agent substantially without irritation to said tissue.
23. The process of claim 22 , wherein said carrier is water soluble.
24. The process of claim 18 , wherein said tissue is in the mouth of a patient and said process comprises placing said composition in the mouth of said patient.
25. The process of claim 22 , wherein said composition further comprises an acid in an amount to form a solution having a pH of less than 6.0.
26. The process of claim 22 , wherein said composition includes at least one acid to form a pH of about 2.0 to about 5.0.
27. The process of claim 25 , wherein said acid is selected from the group consisting of citric acid, acetic acid, malic acid, adipic acid, fumaric acid, ascorbic acid, and mixtures thereof.
28. The process of claim 25 , wherein said carrier is a water soluble solid and said composition comprises ascorbic and citric acid in an amount to form a solution having a pH of less than about 4.0 and said sweetener is saccharin in an amount to suppress pain receptors temporarily on the tissue being treated.
29. The process of claim 22 , wherein said at least one bioactive compound is a pharmaceutically active compound selected from the group consisting of analgesics, antibiotics, antibacterial agents, anti-inflammatory agents, antifungals, immuno-suppressive agents, and mixtures thereof.
30. The process of claim 22 , wherein said carrier is a chewing gum base.
31. The process of claim 22 , wherein said sweetener is selected from the group consisting of saccharin, aspartame, cyclamates, and salts thereof.
32. The process of claim 31 , wherein said composition comprises at least about 10% by of said sweetener.
33. The process of claim 22 , wherein said composition further comprises an alkaline agent.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/200,280 US20030031710A1 (en) | 1999-06-28 | 2002-07-23 | Process and composition for temporarily suppressing pain |
US10/803,090 US20040219110A1 (en) | 1999-06-28 | 2004-03-18 | Process for removing calculus deposits from the teeth and suppressing pain |
US10/803,089 US20040220151A1 (en) | 1999-06-28 | 2004-03-18 | Process for treating tissue and suppressing pain |
US11/109,007 US7223416B2 (en) | 1999-06-28 | 2005-04-19 | Topical composition |
US11/254,014 US7744860B2 (en) | 1999-06-28 | 2005-10-19 | Reduced bioirritant composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/340,111 US6726922B1 (en) | 1999-06-28 | 1999-06-28 | Process and composition for temporarily suppressing pain |
US09/475,473 US6436429B1 (en) | 1999-06-28 | 1999-12-30 | Process and composition for temporarily suppressing pain |
US10/200,280 US20030031710A1 (en) | 1999-06-28 | 2002-07-23 | Process and composition for temporarily suppressing pain |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/475,473 Division US6436429B1 (en) | 1999-06-28 | 1999-12-30 | Process and composition for temporarily suppressing pain |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/803,089 Continuation-In-Part US20040220151A1 (en) | 1999-06-28 | 2004-03-18 | Process for treating tissue and suppressing pain |
US10/803,090 Continuation-In-Part US20040219110A1 (en) | 1999-06-28 | 2004-03-18 | Process for removing calculus deposits from the teeth and suppressing pain |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030031710A1 true US20030031710A1 (en) | 2003-02-13 |
Family
ID=26991965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/475,473 Expired - Fee Related US6436429B1 (en) | 1999-06-28 | 1999-12-30 | Process and composition for temporarily suppressing pain |
US10/200,280 Abandoned US20030031710A1 (en) | 1999-06-28 | 2002-07-23 | Process and composition for temporarily suppressing pain |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/475,473 Expired - Fee Related US6436429B1 (en) | 1999-06-28 | 1999-12-30 | Process and composition for temporarily suppressing pain |
Country Status (3)
Country | Link |
---|---|
US (2) | US6436429B1 (en) |
AU (1) | AU6056500A (en) |
WO (1) | WO2001000153A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050187199A1 (en) * | 1999-06-28 | 2005-08-25 | Peyman Gholam A. | Topical composition |
WO2014127367A1 (en) * | 2013-02-18 | 2014-08-21 | Glenn Abrahmsohn | Compositions and methods for pain relief without numbness |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436429B1 (en) * | 1999-06-28 | 2002-08-20 | Gholam A. Peyman | Process and composition for temporarily suppressing pain |
US7744860B2 (en) * | 1999-06-28 | 2010-06-29 | Minu Llc | Reduced bioirritant composition |
US20030232094A1 (en) * | 2002-06-12 | 2003-12-18 | Fuller Peter E. | Composition and method for the treatment of skin irritations |
TW200413015A (en) * | 2002-11-19 | 2004-08-01 | Showa Pharm Chem Ind | Dissolving agent for dental calculus and decay |
US7288527B2 (en) * | 2004-04-27 | 2007-10-30 | Oklahoma Medical Research Foundation | Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester |
WO2005123106A1 (en) * | 2004-06-10 | 2005-12-29 | Oklahoma Medical Research Foundation | Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester to treat sunburn and other burns |
US20060045858A1 (en) * | 2004-08-26 | 2006-03-02 | Fuller Peter E | Composition and method for reducing harmful effects of ultraviolet radiation impinging on the skin |
US9161905B2 (en) * | 2005-01-12 | 2015-10-20 | Ocular Research Of Boston, Inc. | Dry eye treatment |
US20110117175A1 (en) * | 2009-11-18 | 2011-05-19 | Rosenbaum Richard J | Sweet analgesic for use in medical procedures or treatments |
WO2020123362A1 (en) | 2018-12-10 | 2020-06-18 | EternaTear, Inc. | Ophthalmic formulations providing durable ocular lubrication |
KR102200213B1 (en) * | 2019-08-28 | 2021-01-11 | 코스맥스 주식회사 | Cosmetic composition for alleviating skin irritation and alleviating skin inflammation comprising sorbitol or its mixture |
US11679078B1 (en) | 2022-03-08 | 2023-06-20 | EternaTear, Inc. | Ophthalmic formulations and related methods |
US11471475B1 (en) | 2022-03-08 | 2022-10-18 | Ralph P. Stone | Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4127645A (en) * | 1976-05-21 | 1978-11-28 | Life Savers, Inc. | Effervescent tablet and method |
US4882153A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for antitussives |
US6436429B1 (en) * | 1999-06-28 | 2002-08-20 | Gholam A. Peyman | Process and composition for temporarily suppressing pain |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277464A (en) | 1975-09-19 | 1981-07-07 | General Foods Corporation | Preventing tooth demineralization using aspartame |
US4291045A (en) | 1976-05-04 | 1981-09-22 | Life Savers, Inc. | Method of reducing dental caries |
US4291017A (en) | 1979-11-19 | 1981-09-22 | Dental Concepts, Inc. | Method for limiting adherence of plaque and dental composition therefor |
US4497835A (en) | 1983-01-10 | 1985-02-05 | Alberta Gas Chemicals, Incorporated | Artificially sweetened beverage mixes and process therefor |
US4554167A (en) | 1984-06-14 | 1985-11-19 | General Foods Corp. | Method for agglomerating aspartame and acid-containing mixes |
US4627980A (en) | 1984-12-21 | 1986-12-09 | Ici Americas Inc. | Hard candy dentifrice formulation and method of treating teeth, mouth and throat therewith to reduce irritation and plaque accumulation |
US5180578A (en) | 1987-01-30 | 1993-01-19 | Colgate-Palmolive Company | Antibacterial antiplaque anticalculus oral composition |
US4980152A (en) | 1987-08-06 | 1990-12-25 | Marion Laboratories | Oral preparation |
US5709873A (en) | 1988-02-26 | 1998-01-20 | Niels Bukh A/S | Method of treating conditions of teeth and their supporting tissue |
US5122365A (en) | 1989-02-15 | 1992-06-16 | Natural White, Inc. | Teeth whitener |
US5114726A (en) | 1989-07-25 | 1992-05-19 | The Nutrasweet Company | Process for preparing aspartame coated organic acid |
US5728397A (en) | 1992-05-12 | 1998-03-17 | Fuisz Technologies Ltd. | Polydextrose product and process |
US5670163A (en) | 1994-06-20 | 1997-09-23 | Kv Pharmaceuticals Company | Long acting GI and esophageal protectant |
US5756107A (en) | 1994-12-21 | 1998-05-26 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
ZA962939B (en) | 1995-04-12 | 1997-10-13 | Quest Int | Oral care compositions. |
AU2814995A (en) | 1995-05-26 | 1996-12-11 | Angelo A. Caputo | Chewing gum with fluoride and citric acid |
US5912274A (en) | 1995-09-22 | 1999-06-15 | Colgate-Palmolive Company | Antiplaque oral composition and method |
US5736175A (en) | 1996-02-28 | 1998-04-07 | Nabisco Technology Co. | Chewing gums containing plaque disrupting ingredients and method for preparing it |
US5866179A (en) | 1996-05-03 | 1999-02-02 | Avant-Garde Technologies & Products S.A. | Medicated chewing gum and a process for preparation thereof |
-
1999
- 1999-12-30 US US09/475,473 patent/US6436429B1/en not_active Expired - Fee Related
-
2000
- 2000-06-28 AU AU60565/00A patent/AU6056500A/en not_active Abandoned
- 2000-06-28 WO PCT/US2000/017684 patent/WO2001000153A1/en active Application Filing
-
2002
- 2002-07-23 US US10/200,280 patent/US20030031710A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4127645A (en) * | 1976-05-21 | 1978-11-28 | Life Savers, Inc. | Effervescent tablet and method |
US4882153A (en) * | 1985-12-20 | 1989-11-21 | Warner Lambert Co. | Confectionery delivery system for antitussives |
US6436429B1 (en) * | 1999-06-28 | 2002-08-20 | Gholam A. Peyman | Process and composition for temporarily suppressing pain |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050187199A1 (en) * | 1999-06-28 | 2005-08-25 | Peyman Gholam A. | Topical composition |
US7223416B2 (en) | 1999-06-28 | 2007-05-29 | Minu, L.L.C. | Topical composition |
WO2014127367A1 (en) * | 2013-02-18 | 2014-08-21 | Glenn Abrahmsohn | Compositions and methods for pain relief without numbness |
Also Published As
Publication number | Publication date |
---|---|
AU6056500A (en) | 2001-01-31 |
US6436429B1 (en) | 2002-08-20 |
WO2001000153A1 (en) | 2001-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2927850B2 (en) | Topical preparations for the treatment of symptoms of teeth and their supporting tissues | |
US6436429B1 (en) | Process and composition for temporarily suppressing pain | |
JP4111916B2 (en) | Composition for alleviating xerostomia and treating related diseases | |
JP5684454B2 (en) | Oral care therapeutic and prophylactic compositions | |
RU2406522C2 (en) | Method of reducing inflammation of oral cavity tissue with application of magnolia extract | |
AU772027B2 (en) | Anti-plaque emulsions and products containing same | |
EP1466003B1 (en) | Herbal composition for improving oral hygiene, and methods of using same | |
US5709873A (en) | Method of treating conditions of teeth and their supporting tissue | |
JPH08505140A (en) | Gum coated with an oral protection composition | |
US7223416B2 (en) | Topical composition | |
US20070098650A1 (en) | Dental formulation | |
JPH07108851B2 (en) | Oral composition for preventing solid pimples | |
US5158764A (en) | Dentifrice | |
US6726922B1 (en) | Process and composition for temporarily suppressing pain | |
US20040220151A1 (en) | Process for treating tissue and suppressing pain | |
JP3060238B2 (en) | Oral composition | |
US20040219110A1 (en) | Process for removing calculus deposits from the teeth and suppressing pain | |
JPH1171253A (en) | Salivation accelerator and composition for oral cavity | |
US10813878B2 (en) | Oral health composition | |
PT836852E (en) | USES OF AMILEXANOX FOR THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF FUNGAL ULCERS | |
US7744860B2 (en) | Reduced bioirritant composition | |
US5409691A (en) | Solution comprising aluminum acetate and glycerin | |
KR100613989B1 (en) | Composition for oral care product including nano silk carrier | |
WO2015036533A1 (en) | Long-acting lubricating system for the mouth | |
WO2006110183A2 (en) | Dental formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MINU, L.L.C., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEYMAN, GHOLAM A.;REEL/FRAME:013886/0570 Effective date: 20030224 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |